Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.

Expert review of clinical pharmacology - 1 Jul 2018

Al Efraij Khalid, FitzGerald J Mark

Abstract excerpt

INTRODUCTION: Asthma is an airway disease characterized by airway inflammation. It is associated with significant morbidity, mortality, and costs to the health-care system and society. Eosinophils and interleukin-5 (IL-5) play a key role in the inflammatory response in T-helper 2-high asthma. IL-5 is pivotal for eosinophil development, maturation, and survival in tissues. Asthma severity has been related to both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Asthma

Share to Eosinophils

Share to Interleukin-5

Share to Severity of Illness Index

Source

Identifiers

PMID: 29972739
DOI: 10.1080/17512433.2018.1496819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.PMID 29972739Read ↗

Benralizumab: The Immuno-Pharmacological State of the ArtSemantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.Semantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Controversies and opportunities in severe asthma.Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity Read ↗

Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic FrontiersSemantic proximity Read ↗

What goes up must come down: biomarkers and novel biologicals in severe asthma.Semantic proximity Read ↗

Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies.Semantic proximity Read ↗

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.